BioNTech to Hold Webcast to Present Early Positive Data from Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2
07/01/2020 - 09:28 AM
MAINZ, Germany, July 01, 2020 (GLOBE NEWSWIRE) -- BioNTech SE st , 2020 at 11:00 a.m. EDT (5:00 p.m. CET) to discuss the preliminary data announced this morning from the ongoing Phase 1/2 trial of its mRNA-based vaccine program against SARS-CoV-2.
To participate in the conference call, please dial the following numbers 10-15 minutes prior to the start of the call and provide the Conference ID: 7176269.
100%; border-collapse:collapse !important;">25%; width:25% ; min-width:25% ;">United States international: 75%; width:75% ; min-width:75% ;">+1 646 741 3167 United States domestic (toll-free): +1 877 870 9135 Germany: +49 692 2222 625
Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page of the Investor Relations section of the Company’s website at https://biontech.de/
About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.
Contact
Investor Relations
Media Relations
BNTX Rankings
#4040 Ranked by Stock Gains
BNTX Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
Germany
City
Mainz
About BNTX
everyone achieves greatness at biontech! as one of the most rapidly growing biotechnology companies in europe, we’re working on revolutionary approaches in the fight against cancer and other diseases. over 400 dedicated, passionate pioneers achieve sensational success and promising breakthroughs time and again by forging new paths – and ensure people all around the world have hope for the future. you too can become a pioneer! http://biontech.de/ http://biontech.de/imprint/
